Literature DB >> 20091252

[Limits and scopes of invasive risk stratification. Do we still need programmed ventricular stimulation?].

Sascha Rolf1, Wilhelm Haverkamp.   

Abstract

Patients with ischemic heart disease and left ventricular systolic dysfunction (ICM), dilated (DCM), hypertrophic (HCM), or arrhythmogenic right ventricular cardiomyopathy (ARVCM) carry a high risk of sudden cardiac death (SCD). Ventricular tachyarrhythmias are most often the cause of SCD, which can be treated with internal cardioverter defibrillators (ICDs). However, a great proportion of these high-risk patients will never experience potentially lethal ventricular arrhythmias, and as such will never be in need of these devices. Given the risks, inconvenience, and costs of ICDs, markers that adequately stratify patients according to their risk of SCD are needed. Programmed ventricular stimulation (PVS) has long been used to identify the patients' risk of SCD. However, the prognostic ability of PVS is only modest and the negative predictive value is poor. As far as patients with ICM are concerned, recent data from the MUSTT and MADIT II trials demonstrate that in patients with a left ventricular ejection fraction between 30% and 40%, inducibility by PVS can help to identify patients who are at particularly increased risk of SCD. The value of PVS in patients with DCM, HCM, and ARVCM for risk stratification of SCD is less clear and the available data even more limited. In these patients, the inducibility of ventricular tachyarrhythmias does not clearly correlate with VT/VF (ventricular tachycardia/ventricular fibrillation) risk, and more importantly, noninducibility does not portend good prognosis. The current German guidelines appreciate these uncertainties of PVS for risk stratification with class IIb recommendations in certain patients with ICM, HCM or ARVCM. In the future, combining the results of invasive PVS with other noninvasive parameters may improve its prognostic value. Furthermore, expanding the role of PVS to guiding therapeutic ablation of ventricular arrhythmias may influence patient's future risk of SCD.

Entities:  

Mesh:

Year:  2009        PMID: 20091252     DOI: 10.1007/s00059-009-3294-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  81 in total

1.  The minimally appropriate electrophysiologic study for the initial assessment of patients with documented sustained monomorphic ventricular tachycardia.

Authors:  A L Waldo; M Akhtar; P Brugada; R W Henthorn; M M Scheinman; D E Ward; H J Wellens
Journal:  J Am Coll Cardiol       Date:  1985-11       Impact factor: 24.094

2.  Atrial induction of ventricular tachycardia: reentry versus triggered automaticity.

Authors:  D P Zipes; P R Foster; P J Troup; D H Pedersen
Journal:  Am J Cardiol       Date:  1979-07       Impact factor: 2.778

3.  Ventricular electrical instability: a predictor of death after myocardial infarction.

Authors:  D A Richards; D V Cody; A R Denniss; P A Russell; A A Young; J B Uther
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

4.  Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial.

Authors:  Kerry L Lee; Gail Hafley; John D Fisher; Michael R Gold; Eric N Prystowsky; Mario Talajic; Mark E Josephson; Douglas L Packer; Alfred E Buxton
Journal:  Circulation       Date:  2002-07-09       Impact factor: 29.690

Review 5.  Arrhythmogenic right ventricular cardiomyopathy: diagnosis and risk stratification.

Authors:  Leif-Hendrik Boldt; Wilhelm Haverkamp
Journal:  Herz       Date:  2009-06       Impact factor: 1.443

6.  Endocardial catheter mapping in patients in sinus rhythm: relationship to underlying heart disease and ventricular arrhythmias.

Authors:  D M Cassidy; J A Vassallo; J M Miller; D S Poll; A E Buxton; F E Marchlinski; M E Josephson
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

7.  Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Authors:  Domenico Corrado; Loira Leoni; Mark S Link; Paolo Della Bella; Fiorenzo Gaita; Antonio Curnis; Jorge Uriarte Salerno; Diran Igidbashian; Antonio Raviele; Marcello Disertori; Gabriele Zanotto; Roberto Verlato; Giuseppe Vergara; Pietro Delise; Pietro Turrini; Cristina Basso; Franco Naccarella; Francesco Maddalena; N A Mark Estes; Gianfranco Buja; Gaetano Thiene
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

8.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

9.  A prospective comparison of programmed ventricular stimulation with triple extrastimuli versus single and double extrastimuli during infusion of isoproterenol.

Authors:  J M Baerman; F Morady; M de Buitleir; L A DiCarlo; W H Kou; S D Nelson
Journal:  Am Heart J       Date:  1989-02       Impact factor: 4.749

10.  The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.

Authors:  Otto Costantini; Stefan H Hohnloser; Malcolm M Kirk; Bruce B Lerman; James H Baker; Barathi Sethuraman; Mary M Dettmer; David S Rosenbaum
Journal:  J Am Coll Cardiol       Date:  2009-02-10       Impact factor: 24.094

View more
  1 in total

1.  Ventricular arrhythmias: from risk assessment for sudden cardiac death to therapeutic intervention.

Authors:  Erik Wissner; Karl-Heinz Kuck
Journal:  Herz       Date:  2009-11       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.